Lars van der Veen

5PUBLICATIONS
60CO-AUTHORS
Molecular targetsInfectious agentsApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (5)

|Oct 09, 2026
PI3Kδ is selectively inhibited by roginolisib by stabilizing the C-terminal helix kα12.

|Oct 09, 2026
The conformation-selective PI3Kδ inhibitor roginolisib in patients with advanced or metastatic cancer, including metastatic uveal melanoma: first-in-human clinical trial.

|Nov 21, 2024
Pancreatic CAF-Derived Autotaxin Drives Autocrine CTGF Expression to Modulate Protumorigenic Signaling.

Fanny Volat, Ragini Medhi, Lauren Z Maggs

|Sep 05, 2023
Non-Clinical Toxicology Evaluation of the Novel Non-ATP Competitive Oral PI3 Kinase Delta Inhibitor Roginolisib.

Lars van der Veen, Michael Schmitt, Marcel A Deken

|Apr 17, 2023
IOA-244 is a Non-ATP-competitive, Highly Selective, Tolerable PI3K Delta Inhibitor That Targets Solid Tumors and Breaks Immune Tolerance.

Zoë Johnson, Chiara Tarantelli, Elisa Civanelli

Pageof 1

Frequent Collaborators

4 joint publications

Giusy Di Conza

3 joint publications

Michael Lahn

2 joint publications

Zoë Johnson

2 joint publications

Amy Fraser